Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 28, Issue 1, Pages 87-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2013.10.008
Keywords
FDG-PET; PET/CT; Interim; Hodgkin; Lymphoma; Response adapted
Categories
Ask authors/readers for more resources
Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is the most accurate tool for staging, treatment monitoring, and response evaluation in Hodgkin lymphoma (HL). Early determination of treatment sensitivity by FDG-PET is the best tool to guide individualized, response-adapted treatment. Several ongoing or recently completed trials have investigated the use of FDG-PET/CT for early response-adapted HL therapy. The results are encouraging, but the data are immature, and PET response-adapted HL therapy is discouraged outside the setting of clinical trials. PET/CT looks promising for selection of therapy in relapsed and refractory disease, but the role in this setting is still unclear.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available